prokofiev wrote:
NEWTOWN, Pa., April 11, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies,
Inc. (TSX:HSM) (NASDAQ:HSDT) (“Helius” or the “Company”) today announced the
pricing of an underwritten public offering of 2,141,900 shares of its Class A
common stock and warrants to purchase 2,141,900 shares of its Class A common
stock at a public offering price of US$7.47 per share (at 1.26 USD/CAD = $9.41) and accompanying warrant, before underwriting discounts and commissions. The net proceeds to
the Company from this offering, after deducting the underwriting discounts,
commissions and estimated offering expenses payable by the Company, are
expected to be approximately $14.1 million. The offering is expected to close
on or about Friday, April 13, 2018, subject to customary closing conditions
including the approval of the Toronto Stock Exchange.
Helius intends to use the net proceeds from this offering primarily to fund
its manufacturing activities for the PoNS device, activities related to its
submissions for marketing authorization of the PoNS device to the FDA and
other regulatory authorities, commercial launch preparations, working capital
and general corporate purposes.
The Company’s Class A common stock has been approved for listing on the Nasdaq
Capital Market and is expected to begin trading thereon under the symbol
“HSDT” on Wednesday, April 11, 2018. The Company’s Class A common stock will
continue to trade on the Toronto Stock Exchange under the Symbol “HSM.”